Information de reference pour ce titreAccession Number: | 00007890-200202150-00011.
|
Author: | First, M. Roy 2 7; Gerber, David A. 3; Hariharan, Sundaram 4; Kaufman, Dixon B. 5; Shapiro, Ron 6
|
Institution: | University of Cincinnati Medical Center, Cincinnati, Ohio 45267; University of North Carolina at Chapel Hill, University of North Carolina Hospitals, Chapel Hill, North Carolina 27514; Medical College of Wisconsin, Milwaukee, Wisconsin 53226; Northwestern University Medical School, Chicago, Illinois 60611; and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 (2) Section of Transplantation, University of Cincinnati Medical Center. (3) University of North Carolina at Chapel Hill, University of North Carolina Hospitals. (4) Medical College of Wisconsin. (5) Northwestern University Medical School. (6) Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center. (7) Address correspondence to: M. Roy First, M.D., Director, Section of Transplantation, University of Cincinnati Medical Center, 231 Bethesda Avenue, Cincinnati, OH 45267-0585.
|
Title: | |
Source: | Transplantation. 73(3):379-386, February 15, 2002.
|
Abstract: | Background. Posttransplant diabetes mellitus (PTDM), associated with the use of immunosuppressants, occurs at varying rates in kidney transplant recipients.
Methods. Five transplant centers conducted a retrospective review of 435 kidney recipients completing at least 6 months of follow-up to determine risk factors, incidence, and management strategies for posttransplant glucose intolerance. A distinction was made between hyperglycemia and diabetes.
Results. The incidence of PTDM was found to be 4.9%. Among tacrolimus-treated patients it was 5.7%, compared with 3.3% among cyclosporine-treated patients (P =0.453). Mean daily maintenance doses of prednisone and mycophenolate mofetil (MMF) were significantly lower in tacrolimus-treated patients. Significantly more tacrolimus-treated patients were prednisone-free (9.0%/0%;P <0.001). Logistic regression analysis revealed that the absence of an antiproliferative agent correlated with the development of PTDM (odds ratio=3.56;P =0.01).
Conclusions. Based on this study, we propose management guidelines specifically for glucose intolerance developing after renal transplantation. Maintenance of blood glucose levels within strict limits is recommended, and the contribution of immunosuppressive agents to the development of PTDM is accounted for. Gradual tapering of prednisone and tacrolimus is proposed for patients who develop PTDM but also bear minimal risk of rejection. Tapering and eventual withdrawal of insulin should be attempted once blood glucose levels normalize. Switching to the alternative calcineurin inhibitor should only be considered as a late intervention. Tacrolimus therapy should be considered even in patients at high risk for diabetes, because the benefit of reduced acute rejection incidence and severity, as demonstrated in other studies, outweighs the risk of PTDM.
(C) 2002 Lippincott Williams & Wilkins, Inc.
|
References: | 1. Gunnarsson R, Arner P, Lundgren G, Magnusson G, Ostman J, Groth CG. Diabetes mellitus: a more-common-than-believed complication of renal transplantation. Transplant Proc 1979; 11: 1280.
2. Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG. Steroid diabetes: a sign of overtreatment with steroids in the renal graft recipient? Scand J Urol Nephrol 1980; 54: 135.
3. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376.
4. Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J. Posttransplant hyperglycemia: increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47: 278.
5. Sumrani NB, Delaney V, Ding Z, et al. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation 1991; 51: 343.
6. Alejandro R, Feldman EC, Bloom AD, Kenyon NS. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38: 698.
7. Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc 1988; 20: 985.
8. David DS, Cheigh JS, Braun DW, Jr Fotino M, Stenzel KH, Rubin AL HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA 1980; 243: 532.
9. Hirano Y, Hisatomi A, Ohara K, Noguchi H. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation 1992; 54: 883.
10. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic [beta]-cell. Transplantation 1995; 59: 1606.
11. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Renal Transplant Study Group. Transplantation 1997; 63: 977.
12. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
13. Pirsch JD. Tacrolimus versus cyclosporine in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative study [Abstract]. FK506 Kidney Transplant Study Group. Transplantation 2000; 69: S113.
14. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834.
15. Gonwa TA, Johnson C, Ahsan N, et al. Two year followup of a randomized multicenter kidney transplant study comparing tacrolimus (PG) + azathioprine (AZA) vs. cyclosporine (Neoral) + mycophenolate mofetil (MMF) vs. tacrolimus + MMF [Abstract]. Transplantation 2000; 69: S113.
16. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875.
17. Kasiske BL, Vazquez A, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11: S1.
18. Gavin JR III . New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1998; 1: 1.
19. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70: S58.
20. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151.
21. Sunayama S, Watanabe Y, Daida H, Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000; 11: 397.
22. Wolfe SM, Lurie P, Sasich LD, Barbehenn E. Information on thiazolidinediones [Letter]. Lancet 2000; 356: 254.
23. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485.
24. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411.
25. Buell JF, Kulkarni S, Grewal HP, et al. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil (MMF) immunosuppression, three-year follow-up [Abstract]. Transplantation 2000; 69: S134.
26. Woodle ES, Buell J, Siegel C, Kulkarni S, Kopelan A, Grewal HP. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. Transplant Proc 1999; 31: 84S.
27. Kaufman DB, Leventhal JR, Fryer JP, Abecassis MI, Stuart FP. Kidney transplantation without prednisone [Abstract]. Transplantation 2000; 69: S133.
28. Margreiter R. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and cyclosporin-microemulsion in renal transplantation [Abstract]. European Tacrolimus vs. Cyclosporin-Emulsion Renal Transplantation Study Group. Transplantation 2000; 69: S112.
|
Language: | English.
|
Document Type: | Clinical Transplantation.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0041-1337
|
NLM Journal Code: | wej, 0132144
|
Annotation(s) | |
|
|